Lesofavumab
Based on 1 Customer Validation
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.27%
- CAS No.: 1807960-57-1
- 분자량:147.08 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
influenza A virus hemagglutinin HA
In Vitro
Lesofavumab (MHAB5553A) binds to a conserved epitope in the vestigial esterase domain of hemagglutinin (HA), a major immunodominant surface glycoprotein on influenza B viruses, and blocks HA-mediated membrane fusion in the endosome[1].
Lesofavumab (46B8) is able to neutralize all eleven IBV strains tested that were associated with human infections spanning >70 years, with IC50 values ranging from 0.58 to 0.95 nM[2].
Lesofavumab (46B8; 0-100 ng/mL) blocks membrane fusion and induces antibody-dependent cellular cytotoxicity (ADCC) in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/2 J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2]
-
Dosage:15 mg/kg
-
Administration:Intravenous administration, single dose, 24, 48 or 72 h post infection
-
Result:Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48 h. Even when given at 72 h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1807960-57-1
-
Appearance Liquid
-
분자량 147.08 kDa
-
Color Colorless to light yellow
-
SMILES
[Lesofavumab]
-
Synonyms
MHAB5553A; RG70026
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421. [Content Brief]
[2]. Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lesofavumab Related Classifications
HY-P99699 Related Classifications
Powered by Bioz